Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

2.710 -0.210 (-7.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 134,385
Open 2.860
Bid (Size) 2.830 (2)
Ask (Size) 2.920 (7)
Prev. Close 2.920
Today's Range 2.640 - 2.890
52wk Range 2.611 - 110.75
Shares Outstanding 171,350,166
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Via Stocktwits
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Via ACCESS Newswire

Performance

YTD
-90.1%
-90.1%
1 Month
-38.5%
-38.5%
3 Month
-47.2%
-47.2%
6 Month
-89.8%
-89.8%
1 Year
-97.2%
-97.2%

More News

Read More
Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs
Via ACCESS Newswire
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026
Via ACCESS Newswire
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Via ACCESS Newswire
Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Via ACCESS Newswire
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Via ACCESS Newswire
REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Via ACCESS Newswire
Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Via ACCESS Newswire
Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series
Via ACCESS Newswire
Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
First Patient Randomized in Jaguar Health’s Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Jaguar Health Reports First Quarter 2025 Financials
Via ACCESS Newswire
Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates
Via ACCESS Newswire
Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Via ACCESS Newswire
Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts
Via ACCESS Newswire
Earnings Scheduled For May 15, 2025
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease
Via ACCESS Newswire
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Via ACCESS Newswire
Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
Via ACCESS Newswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill

Frequently Asked Questions

Is Jaguar Health, Inc. - Common Stock publicly traded?
Yes, Jaguar Health, Inc. - Common Stock is publicly traded.
What exchange does Jaguar Health, Inc. - Common Stock trade on?
Jaguar Health, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jaguar Health, Inc. - Common Stock?
The ticker symbol for Jaguar Health, Inc. - Common Stock is JAGX on the Nasdaq Stock Market
What is the current price of Jaguar Health, Inc. - Common Stock?
The current price of Jaguar Health, Inc. - Common Stock is 2.710
When was Jaguar Health, Inc. - Common Stock last traded?
The last trade of Jaguar Health, Inc. - Common Stock was at 06/26/25 04:00 PM ET
What is the market capitalization of Jaguar Health, Inc. - Common Stock?
The market capitalization of Jaguar Health, Inc. - Common Stock is 464.36M
How many shares of Jaguar Health, Inc. - Common Stock are outstanding?
Jaguar Health, Inc. - Common Stock has 464M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.